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FIG 1. Absolute TEWL before and after skin pretreatment with either
abrasion (A) or tape-stripping (B). Data are shown asmean6 SEM, compar-
ison by Wilcoxon signed rank test. C, Comparison of change in TEWL after
abrasion and tape-stripping by using the Mann-Whitney test. Box plots
indicate the median, the 10th, 25th, 75th, and 90th percentiles, and outliers.
***P < .001.
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Comparing safety of abrasion and tape-
stripping as skin preparation in allergen-
specific epicutaneous immunotherapy
To the Editor:
Development of cutaneous delivery systems enabling needle-
free and self-administrable vaccine administration is one impor-
tant approach to improve global health care.
Passing the epidermal barrier structures is a challenge to the
successful delivery of antigens: (1) the stratum corneum,
composed of cornified keratinocytes surrounded by lipids, and
(2) tight junctions in the stratum granulosum, providing ion and
size selectivity.1 Langerhans cells (LCs), able to capture antigen
and induce adaptive immune responses, are found below these
2 barrier structures.1 For efficient induction of immune responses,
LCs need to be activated to elongate their dendrites through the
tight junctions. Whether physical epidermal barrier disruption is
necessary for efficient antigen capture is still a matter of debate.
Recently, a transcutaneous vaccine delivery platform was
developed by Intercell and approved for prophylactic vaccination
against Japanese encephalitis. For efficient immunization, an
abrasive skin preparation system is used before vaccine delivery,
based on trials showing direct correlation between degree of skin
disruption and magnitude of antibody responses.2,3 Besides facil-
itating skin permeability, mechanical barrier-disruption also acti-
vates and polarizes LCs through the release of cytokines acting as
adjuvant.4
We recently demonstrated the efficacy of epicutaneous immu-
nization in allergy immunotherapy5,6 using adhesive tape-
stripping for skin preparation and found higher allergen doses
showing higher clinical efficacy.5 We therefore aimed to enhance
allergen delivery by using abrasion rather than tape-stripping for
skin preparation as shown for other transcutaneous vaccines.3
However, enhanced skin disruption may represent a safety risk
in allergic individuals.
A detailed methodology is given in this article’s Online
Repository at www.jacionline.org. Briefly, a total of 98 grass-pol-
len–allergic patients were included and randomly assigned to
receive placebo epicutaneous allergen-specific immunotherapy
(EPIT) (1.5 mL petrolatum) or allergen EPIT (1.5 mL allergen-
extract, Stallergenes, 200 IR/mL). Before application of the first
patch, 2 skin-preparation procedures were tested: abrasion with
a foot-file (52 patients: 26 placebo and 26 allergen) or adhesive
tape-stripping (45 patients: 21 placebo and 24 allergen) (see Fig
E1 in this article’s Online Repository at www.jacionline.org).
The degree of skin disruption was measured by transepidermal
water loss (TEWL) before and after skin preparation. For safety,
patients were observed for 30 minutes and local immediate-type 2014 The Authors. Published by Elsevier Inc. on behalf of the American Academy of
Allergy, Asthma & Immunology. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).reactions such as erythema and pruritus were assessed 10 and
30 minutes after patch application. Pruritus intensity was rated
on a visual analog scale from 0 to 100. The patch was removed
after 8 hours. Delayed-type reactions, such as eczema, weremoni-
tored by phone call 48 hours after patch application.
Both skin-preparation methods, abrasion (Fig 1, A) and tape-
stripping (Fig 1, B), resulted in significantly increased TEWL
when compared with baseline (P < .0001). The mean change in
TEWL after abrasion, 10.20 g/m2/h (median, 7 g/m2/h; 95% CI,
7.64-12.75), was significantly higher than after tape-stripping,
3.71 g/m2/h (median, 3 g/m2/h; 95% CI, 2.74-4.67) (Fig 1, C;
P < .0001). Correspondingly, local immediate-type reactions
such as pruritus appeared faster and significantly stronger after
allergen EPIT with abrasion as compared with allergen EPIT
with tape-stripping (Fig 2, A and B). Indeed, a strong correlation
was observed between change in TEWL and pruritus intensity
(Fig 2, D and E; P 5 .0015). Again, erythema (Fig 2, C) was
significantly stronger after allergen EPITwith abrasion (mean er-
ythema size, 58.44 6 32.36 cm2) than after allergen EPIT with
tape-stripping (6.256 19.32 cm2) and significantly more frequent
(P < .001). Local eczema was reported only after allergen EPIT: 7
FIG 2. Local itching intensity recorded by VAS 10 minutes (A) and 30 minutes (B) after different EPIT pre-
treatments. C, Erythema size 30 minutes after treatment. Group comparison by using the Kruskal-Wallis
test. ***P < .001, **P < .01, and *P < .05. Correlation between itching intensity by VAS and change in
TEWL 10 minutes (D) and 30 minutes (E) after allergen EPIT. Patients with systemic allergic reaction after
abrasion are depicted as open circles and after tape-stripping are depicted as triangles. (One patient
suffering from a systemic allergic reaction after abrasion showing TEWL change of 35 g/m2/h is omitted
in Fig 2, E, because the corresponding VAS value is missing.) ns, Nonsignificant; VAS, visual analog scale.
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stripping (P 5 .41).
Systemic allergic reactions were observed in 6 patients after
allergen EPIT with abrasion and in 1 patient after allergen EPIT
with tape-stripping (P5 .10; see Table E1 in this article’s Online
Repository at www.jacionline.org). When pooling results of our
previous trials,5,6 systemic reaction frequency after abrasion
was significantly higher than after tape-stripping (P 5 .033; see
Table E2 in this article’s Online Repository at www.jacionline.
org). All patients with a change in TEWL higher than 20 g/m2/h
experienced a systemic allergic reaction (Fig 2, D and E).
Concluding on our study, stronger skin-barrier disruption after
abrasion than after tape-stripping was associated withsignificantly stronger local pruritus and erythema size, and a
more systemic allergic reaction, indicating that safety is likely
more critical in allergen EPIT than for other vaccines. As a
comparison, skin preparation by abrasion using the skin prepa-
ration system before transcutaneous vaccination for E coli–
induced traveller’s diarrhea was completely safe.3 Reported
average change in TEWL was 12.9 g/m2/h and even vaccines
with changes in TEWL between 20 g/m2/h and 70 g/m2/h did
not show any systemic adverse effects,3 whereas in allergen
EPITall patients with changes in TEWL above 20 g/m2/h suffered
from systemic allergic reactions. Hence, although strong skin-
barrier disruption is unproblematic in transcutaneous prophylac-
tic vaccination, it seems dangerous in allergen EPIT, where
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amount of allergen penetrates beyond the nonvascularized
epidermis toward the dermal vasculature, systemic allergic reac-
tions are frequent, as observed in 6 patients after abrasion. In
contrast, only 1 patient developed a systemic allergic reaction af-
ter tape-stripping, which has been shown to primarily affect the
stratum corneum, with allergen deposition in epidermal layers.7
Eczema was reported after allergen EPIT with abrasion and
with tape-stripping but in no patient after placebo EPIT. Please
note patient self-reporting of eczema as a weakness of this study.
The frequency of adverse effects after allergen EPITwith tape-
stripping is comparable to our previous experience5,6 (see Table
E2) except for 2 striking differences: (1) in the first study with
48-hour patch administration time, more eczema reactions were
reported, and (2) in the present subanalysis, the number of sys-
temic adverse effects was more than doubled when using abrasion
than when using tape-stripping.
As a limitation, we could not show statistical significance for
difference in systemic allergic reaction frequency after allergen
EPITwith abrasion and tape-stripping when strictly using data of
the present subanalysis of ClinicalTrials.gov NCT00777374.
Because end points were efficacy and immunological changes,
no power calculations were done for the present retrospective
analysis. As another limitation, skin abrasion using a foot-file is
difficult to standardize and the procedure was performed by
different study team members. Furthermore, because abrasion
had to be stopped prematurely for safety reasons, no analysis
with respect to enhanced efficacy could be performed.
Also, it would be interesting to measure the modulation of
immune responses after abrasion versus tape-stripping because
the degree of skin disruption has been suggested to play a role in
polarizing TH1, TH2, or T-regulatory-cell–type responses by acti-
vating different subsets of skin-resident antigen-presenting cells.8
Skin-barrier disruption has been reported to favor TH2-polarized
immune responses,1 while hydration-facilitated antigen delivery
on nondisrupted skin favors T-regulatory-cell responses.9 Hence,
skin-barrier disruption would seem disadvantageous for allergen
immunotherapy. Nevertheless, we previously showed the thera-
peutic efficacy of allergen EPITwith tape-stripping.5,6 Therefore,
the effects of different methods for skin disruption on T-cell polar-
ization are so far unclear.
Here, we highlight that different skin-disruption methods must
also be compared for safety, adding another layer of complexity in
the field of allergy immunotherapy.
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IgE antibodies to mountain cedar pollen pre-
dominantly recognize multiple conformational
epitopes on Jun a 1
To the Editor:
Recent analyses of several databases of allergens provide
evidence for structural similarities of allergenic proteins.1 The
707 allergens with known sequences belong to only 184 (;2%)
of the 9318 protein families (Pfams).2 Furthermore, of the rare
Pfams that contain an allergen, 81 contain multiple allergens
and 10 Pfams with the most allergens contain 300 (42%) aller-
gens. The congruence of pollen allergens with structural families
is evenmore apparent. Of the 157 pollen allergens with known se-
quences, 93 (59%) reside in just 5 Pfams,3 suggesting that pollen
allergens share a very limited number of relatively unique struc-
tures. Identifying the common structural features of allergens
may help to elucidate their unique structural elements and poten-
tially the mechanism(s) for their allergenicity.
The goal of our research was to use the highly allergenic
mountain cedar (Juniperus ashei, Cupressaceae) pollen as a
model for characterizing the allergenicity of individual proteins
and to identify the structural elements that are required for
allergic sensitization or reactions.4 In the current study, we first
quantified patient IgE antibodies to crude extract of cedar pollen
and to purified Jun a 1,5 a major mountain cedar allergen, using
ImmunoCap technology (Phadia, Uppsala, Sweden). The vast
majority (median, 93%) of IgE antibodies to cedar pollen in the
serum from 35 allergic subjects (34 subjects; see Table E2 in
this article’s Online Repository at www.jacionline.org) reacted
with Jun a 1 (see Fig E1 in this article’s Online Repository at
www.jacionline.org).
To define the fine specificity and complexity of these anti-
bodies, we chose 7 serawith high concentrations of IgE anti–Jun a
1 antibodies and adequate serum volume to assess the relative
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Clinical trial design and participants
This study was a retrospective analysis of a single-center phase I/IIa,
placebo controlled, randomized, double-blind study conducted at the Clinical
Trials Center of the University Hospital of Zurich, Switzerland (ClinicalTrials.
gov NCT00777374). The study was designed to test safety and clinical effi-
cacy of EPIT. Two different skin preparation procedures were tested before
application of the first EPIT patch: adhesive tape-stripping and abrasion using
a foot-file.
A total of 98 patients were enrolled. Inclusion criteriawere signed informed
consent, age between 18 and 65 years, and a history of grass-pollen–allergic
rhinoconjunctivitis with positive skin prick and conjunctival provocation test
results. Patients with eczematous skin lesions on the upper arms, perennial
allergic rhinitis, moderate to severe asthma, mastocytosis, malignancy, active
infectious disease, or significant systemic illness or if pregnant or nursingwere
excluded. Those using the following drugs were excluded from study
participation: antihistamines with a long half-life within the last week,
systemic or topical steroids within the last 5 days, beta-blockers, immuno-
suppressive agents, angiotensin-converting enzyme inhibitors, angiotensin II
antagonists, steroid inhalers, or tricyclic antidepressants.
Study procedures and skin pretreatment methods
The first of the 6 patches was administered in January 2009, that is,
approximately 3months before the start of the grass pollen season. The skin on
the upper arm was prepared by either adhesive tape-stripping or abrasion and
the patch was then applied for 8 hours. Adhesive tape-stripping was performed
10 times on an area of 16 cm2 using a scotch tape (ScotchMagic Tape 810, 3M
Company, St Paul, Minn). A new tapewas used for each of the 10 strips. Abra-
sion was performed with a commercially available foot file (Pedic Care, Mi-
gros, Switzerland) with a 100 grit size. The file was applied once
tangentially by trained study personnel.
Patch and test drug
The patch system was provided by Medanz Medical GmbH (Starnberg,
Germany). The allergen extract of 5 grasses (Dactylis glomerata, Agrostis sto-
lonifera, Phleum pratense, Poa pratensis, and Anthoxanthum odoratum) was
purchased from Stallergenes (Antony, France) with a biological activity of
200 IR/mL suspended in white petrolatum. Individual patches were manufac-
tured by the cantonal pharmacy of Zurich and loaded with 1.5 mL of allergen
extract or with placebo (white petrolatum only). This allergen concentration
and formulation was already used in our first trial.E1
TEWL measurement
Measurement of TEWL is a common method used for the assessment of
stratum corenum barrier function.E2 The TEWL was measured with the Der-
maLab USB device (Hadsund, Denmark) before and after skin pretreatment as
described.E3 The patients had 15minutes acclimatization to room temperature
before the TEWL assessment. The probe was held with isolating latex gloves
and then placed onto the untreated skin area for acquisition of baseline TEWL.
Thereafter, the skin was treated either by tape-stripping or by abrasion, and the
TEWL was measured again. The TEWL values were noted once steady state
had been reached. Change in the TEWL was calculated by subtraction of the
individual baseline value from the post-treatment value.
Safety
After patch application, patients were supervised for 30 minutes in the
clinical trials facility. If no systemic events were observed, patients were
discharged with an emergency set containing the antihistamine levocetirizine20 mg (UCB Phama, Bulle, Switzerland) as well as prednisone 100 mg
(Streuli, Uznach, Switzerland).
Local itching at the patch application site was assessed 10 and 30 minutes
after patch application using a visual analogue scale ranging from 0 to 100. At
the same time, erythema size was measured. Forty-eight hours after patch
application, patients were contacted by phone to assess local late-type
eczematous skin reaction. Local eczematous skin reactions were graded
according to the criteria of atopy patch test after the revised European Task
Force on atopic dermatitis key for atopy patch test readingE4: ‘‘2’’ negative;
‘‘?’’ only erythema; ‘‘1’’ erythema, infiltration; ‘‘11’’ erythema, few papules;
‘‘111’’ erythema, many or spreading papules; ‘‘1111’’ erythema,
vesicles.
Systemic allergic reactions as a response to patch application were graded
according to the EAACI Immunotherapy Task ForceE5: Grade 0: nonspecific
reactions such as discomfort, headache, and arthrlagia; grade 1: mild systemic
reactions such as localized urticaria, rhinitis, or mild asthma (peak plow [PF]
<20% decrease from baseline); grade 2: moderate systemic reactions such as
slow onset (>15 minutes) of generalized urticaria and/or moderate asthma (PF
<40% decrease from baseline); grade 3: severe (not life-threatening) systemic
reactionswith rapid onset (<15minutes) of generalized urticaria, angioedema,
or severe asthma (PF >40% decrease from baseline); grade 4: anaphylactic
shock with immediately evoked reaction of itching, flushing, erythema, gener-
alized urticaria, stridor (angioedema), immediate asthma, hypotension.
Statistical analysis
Because this study is retrospective analysis of a clinical trial determining
the safety and efficacy of allergen EPIT by comparing it to placebo EPIT
(ClinicalTrials.gov NCT00777374), sample size calculation was powered to
show the clinical efficacy of allergen EPIT compared with that of placebo
EPIT. No sample size was calculated for this subanalysis to show difference
in systemic allergic reactions between different skin pretreatment groups.
Statistical analyses were performed using the Graph pad software.
Gaussian distribution was tested using D’Agostino and Pearson normality
test. Wilcoxon matched pairs test was used to compare values before and after
skin pretreatment. For intergroup comparison of nonparametric data, 2-way
MannWhitneyU test was applied.Multiple group comparisonwas done using
the Kruskal Wallis test with Dunn’s multiple comparison tests. Correlation
was analyzed using the Spearman test. The frequency of systemic and local
allergic reactions (erythema and eczema) after allergen EPIT occurring in
the different pretreatment groups was compared using Fisher exact test with
mid-P adjustment.
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FIG E1. Participant flow. Flow diagram showing patient allocation to
different study groups and different skin pretreatment procedures before
the application of the first EPIT patch. One patient to receive placebo EPIT
with tape-stripping declined further participation.
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TABLE E1. Systemic allergic reactions
Systemic allergic
reaction
Abrasion Tape-stripping
Allergen
(n 5 26)
Placebo
(n 5 26)
Allergen
(n 5 24)
Placebo
(n 5 21)
Grade I 1 0 0 0
Grade II 5 1 1 0
Grade III 0 0 0 0
Grade IV 0 0 0 0
Total, n (%) 6 (23) 1 (3.8) 1 (4.2) 0
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TABLE E2. Comparison of EPIT trials
Trial characteristic First trial (pollen season 2006)E1
Second trial (pollen season 2007)E6
NCT00719511
Third trial (pollen season 2009)
NCT00777374
Allergen extract 5 Graminees, Stallergenes, France 6 Graminees, Inmunotek, Spain 5 Graminees, Stallergenes, France
Solvent Petrolatum Glycerol 50% Petrolatum
Allergen extract potency 200 IR/mL, 1.5 mL 5 21 mg Phl p 5 10 HEP/mL, 1 mL 5 3 mg Phl p 5
50 HEP/mL, 1 mL 5 15 mg Phl p 5
100 HEP/mL, 1 mL 5 30 mg Phl p 5
200 IR/mL, 1.5 mL 5 21 mg Phl p 5
Skin preparation Tape-stripping 63 Tape-stripping 63 Tape-stripping 103
Before first patch (subanalysis)
Tape-stripping/abrasion
Duration of patch application (h) 48 8 8
Number of patches 12 6 6
Safety: Eczema (eczema/total patch
applications)
160/252 (63.5%) 10 HEP: 29/174 (16.6%)
50 HEP: 51/171 (29.8%)
100 HEP: 44/171 (25.7%)
48/265 (18.1%) in total
Before first patch (subanalysis)
Tape-stripping: 4/24 (16.6%)
Abrasion: 7/26 (26.9%)
Safety: Systemic adverse effects/total
patients
0/21 (0%) 10 HEP: 3/33 (9%)
50 HEP: 3/33 (9%)
100 HEP: 4/33 (12%)
Tape-stripping: 1/24 (4%)
Abrasion: 6/26 (23%)
Total (pooled analysis)
Number of patients with systemic
adverse effects/number of patients
without systemic reaction
Tape-stripping: 11/133
Abrasion: 6/20
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